Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 19;10(9):1129.
doi: 10.3390/antibiotics10091129.

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center

Lucia Brescini  1   2 , Filippo Della Martera  1   2 , Gianluca Morroni  2 , Sara Mazzanti  1   2 , Maria Di Pietrantonio  1   2 , Paolo Mantini  1   2 , Bianca Candelaresi  1   2 , Francesco Pallotta  1   2 , Silvia Olivieri  1   2 , Valentina Iencinella  2   3 , Sefora Castelletti  3 , Emanuele Cocci  4 , Rosaria G Polo  4 , Salvatore Veccia  1 , Oscar Cirioni  1   2 , Marcello Tavio  3 , Andrea Giacometti  1   2
Affiliations

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center

Lucia Brescini et al. Antibiotics (Basel). .

Abstract

Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin.

Methods: We carried out a retrospective study of the use of dalbavancin in 55 patients at the Azienda Ospedaliera Ospedali Riuniti Umberto I (Ancona, Italy) from February 2017 to May 2020 and compared "on label" and "off label" use of dalbavancin in ABSSSI and non-ABSSSI.

Results: A total of 55 patients were included in the study. The median age was 61 years; 51% had ABSSSI; 24% had prosthetic joint infections, and 14% had osteomyelitis. A total of 53% received a single 1500 mg infusion of dalbavancin, and 18% received a second dose 14 days later; 24% of patients received further doses at 14-day intervals. In 91% of cases, patients achieved clinical objectives with dalbavancin: 96% of patients with ABSSSI and 69% of those with prosthetic joint infections.

Conclusions: Dalbavancin was shown to have an excellent tolerability profile and to be a highly successful therapeutic approach even in those cases treated "off-label".

Keywords: ABSSSI; dalbavancin; osteomyelitis; prosthetic joint infections.

PubMed Disclaimer

Conflict of interest statement

The funding sponsors did not have any role in the choice of research project; design of the study; in the collection, analyses or interpretation of data; in the writing of the manuscript; or in the decision to publish.

Figures

Figure 1
Figure 1
Clinical outcomes after dalbavancin application.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Simonetti O., Rizzetto G., Molinelli E., Cirioni O., Offidani A. Review: A Safety Profile of Dalbavancin for On- and Off-Label Utilization. Ther. Clin. Risk Manag. 2021;17:223–232. doi: 10.2147/TCRM.S271445. - DOI - PMC - PubMed
    1. Dunne M.W., Puttagunta S., Giordano P., Krievins D., Zelasky M., Baldassarre J. A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection. Clin. Infect. Dis. 2016;62:545–551. doi: 10.1093/cid/civ982. - DOI - PMC - PubMed
    1. David M.Z., Dryden M., Gottlieb T., Tattevin P., Gould I.M. Recently Approved Antibacterials for Methicillin-Resistant Staphylococcus Aureus (MRSA) and Other Gram-Positive Pathogens: The Shock of the New. Int. J. Antimicrob. Agents. 2017;50:303–307. doi: 10.1016/j.ijantimicag.2017.05.006. - DOI - PubMed
    1. Simonetti O., Lucarini G., Morroni G., Orlando F., Lazzarini R., Zizzi A., Brescini L., Provinciali M., Giacometti A., Offidani A., et al. New Evidence and Insights on Dalbavancin and Wound Healing in a Mouse Model of Skin Infection. Antimicrob. Agents Chemother. 2020;64:e02062-19. doi: 10.1128/AAC.02062-19. - DOI - PMC - PubMed
    1. Bassetti M., Peghin M., Carnelutti A., Righi E. The Role of Dalbavancin in Skin and Soft Tissue Infections. Curr. Opin. Infect. Dis. 2018;31:141–147. doi: 10.1097/QCO.0000000000000430. - DOI - PubMed

Grants and funding

LinkOut - more resources